Ticker LaunchUplisting · BCDA
BioCardia, Inc.
Formerly Tiger X Medical, Inc.; Cardo Medical, Inc.; CLICKNSETTLE COM INC
BioCardia, Inc. (BCDA), already reporting to the SEC, moved up to Nasdaq Capital Market on Aug 5, 2019 with an offering at $6.00 per share raising $10M. Maxim Group was lead-left underwriter, joined by Brookline and Dawson James. Wilson Sonsini advised the company and Loeb & Loeb advised the underwriters.
BioCardia, Inc. is a clinical-stage regenerative medicine company developing cardiovascular therapies. Its lead candidate, the CardiAMP Cell Therapy System, is an autologous bone marrow cell therapy being studied for heart failure after a heart attack and for chronic myocardial ischemia.
- Status
- Uplisting
- Ticker
- BCDA
- Exchange
- Nasdaq Capital Market
- Listed
- Aug 5, 2019
- Price
- $6.00
- Raised
- $10M
- Market cap at IPO price
- $40.4M
- First filed
- Dec 18, 2009
- Underwriters
- Maxim Group, Brookline and Dawson James
- Company counsel
- Wilson Sonsini
- Underwriters' counsel
- Loeb & Loeb
- Sector
- Biotech & pharma
- Country / state
- CA
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Dec 18, 2009
- Latest amendment Aug 1, 2019
- Final prospectus (424B4) Aug 5, 2019
- All filings on EDGAR CIK 925741
Other Biotech & pharma uplistings in 2019
- Artelo Biosciences, Inc.ARTL · Jun 25, 2019 · $8M
- Guardion Health Sciences, Inc.GHSI · Apr 8, 2019 · $5M
- Chemomab Therapeutics Ltd.ANCN · Feb 13, 2019 · $30.5M